Mouse VEGFR3 quantitates mouse VEGFR3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant mouse VEGFR3.
Accession number
AI323512 ; Chy ; ascites chyleux ; FLT4 ; FLT-4 ; FLT41 ; tyrosine kinase 4 lié au fms ; tyrosine kinase 4 semblable au FMS ; tyrosine kinase 4 lié au fms ; LMPH1A ; PCL ; proteins-tyrosine kinases des récepteurs ; VEGFR 3 soluble ; sVEGFR 3 ; récepteur de tyrosine-protein kinase FLT4 ; récepteur de facteur de croissance endothélial vasculaire 3 ; récepteur de facteur de croissance endothélial vasculaire 3 ; VEGF R3 ; Vegfr3 ; VEGFR-3
Dose range
0.2 to 50 ng/ml
Sensitivity of the dosage
0.2 ng/ml
Conjugate
Biotin
Product type
ELISA
Brand
Invitrogen
Mouse VEGFR3 quantitates mouse VEGFR3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant mouse VEGFR3.
Mouse VEGFR3 quantitates mouse VEGFR3 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant mouse VEGFR3.
Vascular endothelial growth factor is a key regulator of the development of blood vessels in embryos and l-angiogenesis in adult tissues. Unlike VEGF, VEGFC as a combination stimulates the growth of lymphatic vessels through its specific VEGFR-3 lymphatic endothelial receptor. In 1998, Dumont showed that the targeted inactivation of the VEGFR-3 gene in mice resulted in defective development of blood vessels in early embryos. Vasculogenesis and benzogenesis occurred, but large vessels became abnormally organized with defective lumens, resulting in fluid accumulation in the pericardial cavity and cardiovascular failure on embryonic day 9.5. Thus, VEGFR3 plays a key role in the development of the embryonic cardiovascular system before the emergence of lymphatic vessels.